Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,241
  • Shares Outstanding, K 75,420
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,560 K
  • 60-Month Beta 1.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.26
Trade ONCY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.09
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +21.78%
on 04/16/24
1.2300 unch
on 05/06/24
+0.0800 (+6.96%)
since 04/05/24
3-Month
0.8830 +39.30%
on 02/07/24
1.2900 -4.65%
on 04/04/24
+0.1800 (+17.14%)
since 02/06/24
52-Week
0.8830 +39.30%
on 02/07/24
3.3942 -63.76%
on 06/23/23
-0.3700 (-23.13%)
since 05/05/23

Most Recent Stories

More News
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

/CNW/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...

ONCY : 1.2300 (+5.13%)
CELC : 17.67 (+0.06%)
OLMA : 10.67 (+5.96%)
BIO : 279.83 (+0.19%)
AZN : 75.88 (-0.62%)
ONC.TO : 1.60 (+0.63%)
Biotech's Developments in Race Against Rising Cancer Rates Revealed

USA News Group – According to a “highly troubling” new study, the rising number of cancer cases in young people is being attributed to “accelerated aging.” Further alarm is being spread by the...

ONCY : 1.2300 (+5.13%)
ONC.TO : 1.60 (+0.63%)
CELC : 17.67 (+0.06%)
OLMA : 10.67 (+5.96%)
BIO : 279.83 (+0.19%)
AZN : 75.88 (-0.62%)
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

/CNW/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In...

ONCY : 1.2300 (+5.13%)
ICCM : 1.1900 (+0.85%)
ATOS : 1.6700 (+0.60%)
ARVN : 32.82 (+1.20%)
PFE : 27.92 (+0.40%)
ONC.TO : 1.60 (+0.63%)
Biotech Firms Intensify Efforts as Breast Cancer Strikes Younger Patients at Alarming Rate

USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is...

ONCY : 1.2300 (+5.13%)
ONC.TO : 1.60 (+0.63%)
ICCM : 1.1900 (+0.85%)
ATOS : 1.6700 (+0.60%)
ARVN : 32.82 (+1.20%)
PFE : 27.92 (+0.40%)
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 1.2300 (+5.13%)
ONC.TO : 1.60 (+0.63%)
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the...

ONCY : 1.2300 (+5.13%)
ONC.TO : 1.60 (+0.63%)
Biotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Cases

USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common...

ONCY : 1.2300 (+5.13%)
ONC.TO : 1.60 (+0.63%)
GILD : 64.90 (+0.19%)
GTHX : 4.50 (+0.22%)
AZN : 75.88 (-0.62%)
HOLX : 76.49 (-0.07%)
Biotech Innovations Paving the Way in Breast Cancer Fight

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END

ONCY : 1.2300 (+5.13%)
ONC.TO : 1.60 (+0.63%)
GILD : 64.90 (+0.19%)
GTHX : 4.50 (+0.22%)
AZN : 75.88 (-0.62%)
HOLX : 76.49 (-0.07%)
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic breast...

ONCY : 1.2300 (+5.13%)
ONC.TO : 1.60 (+0.63%)
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to...

ONCY : 1.2300 (+5.13%)
ONC.TO : 1.60 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.2167
2nd Resistance Point 1.2033
1st Resistance Point 1.1867
Last Price 1.2300
1st Support Level 1.1567
2nd Support Level 1.1433
3rd Support Level 1.1267

See More

52-Week High 3.3942
Fibonacci 61.8% 2.4349
Fibonacci 50% 2.1386
Fibonacci 38.2% 1.8423
Last Price 1.2300
52-Week Low 0.8830

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar